BXP Selling 7 Times Square Ground Lease

Boston Properties (BXP) is marketing the 7 Times Square ground lease via Eastdil Secured, hiring Will Silverman and Gary Phillips. BXP expects proceeds of $700 million to $750 million, with bids due soon. The 1.2M sq ft tower has a 99-year lease and is 91% occupied. The deal would test Times Square office demand.

Original reporting
Published Jul 20, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 20, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BXP Selling 7 Times Square Ground Lease — source image
Decision brief

The 30-second read

$BXPNeutralMed
01

Why it matters

If executed near the low end, the sale would support BXP’s stated plan to deleverage and reinvest, but the office-market test could also reveal weaker pricing power if bids come in below expectations.

02

Market read

A concrete, near-term disposition process with explicit proceeds guidance makes this a tradable catalyst for BXP’s capital recycling narrative.

03

What to watch

Tenant credit and lease rollover risk at 7 Times Square, plus the 99-year ground lease structure and city purchase option, could materially affect buyer appetite and final pricing.

Relevance 7/10Novelty 6/10Timing: Bids for the 7 Times Square ground lease are due soon after the marketing announcement.

Background

BXP is marketing the 1.2M sq ft Times Square Tower ground lease (99-year term from 1990) as part of strategic dispositions.

Company-level read

Ticker impact

$BXPNeutralMedium confidence
Context

BXP is marketing the 7 Times Square ground lease, seeking $700M to $750M, with bids due soon.

Expected impact

Moderate positive bias if deal pricing clears the low end of the stated range; otherwise limited upside.

Evidence & confidence

This is a fresh, company-specific disposition headline with explicit target proceeds and timing (bids due soon), but no confirmed buyer or executed price yet.

Market effects

Signals continued monetization of large office assets in gateway markets, with pricing discipline around $700M+ single-property trades.

Highlights ongoing repositioning pressure in Times Square office stock versus residential and hotel conversions nearby.

Limited direct global impact, but reinforces broader commercial real estate capital recycling themes.

Counterpoint

The stated $700M+ range may reflect a high bar for office risk, so failure to attract strong bids could pressure sentiment on BXP’s disposition pipeline.

Key entities

  • BXP

    Boston Properties, marketing the 7 Times Square ground lease and targeting $700M to $750M proceeds.

  • Eastdil Secured

    Real estate firm hired to market the ground lease.

  • Norges Bank Investment Management

    Paid $684M in 2013 for a 45% stake in the property referenced in the article.

  • RXR

    Neighbor at 5 Times Square converting to residential units, cited as local competitive context.

  • SL Green Realty

    Considering converting 1515 Broadway into a hotel, cited as local competitive context.

Related articles

$BXPMed

BXP, Inc. Q2 2026 Earnings Call Summary

Strategic Performance and Market Dynamics BXP delivered a strong second quarter, exceeding FFO guidance by $0.08 and raising the 2026 midpoint by $0.05, driven by faster-than-expected leasing and occupancy gains. Management attributes the leasing momentum to a 'very healthy environment' for premier workplaces, noting that AI is acting as a significant tailwind by driving space expansions and upgrades among tech and professional service firms.

$BXPMed

BXP Secures $1.2B Construction Loan for 343 Madison Avenue Office Tower – Commercial Observer

BXP announced it secured a $1.2B construction loan for its 930,000 sq ft, 46-story office tower at 343 Madison Ave in Midtown, with a four-year term plus a one-year extension option, from Wells Fargo, Bank of America Securities, BNY Mellon and J.P. Morgan. Completion is set for 2029; the project is 50% pre-leased. BXP reported Q2 2026 FFO of $283.4M ($1.78/share) and revenue of $895.7M.

$BXPMed

Q3 Financial Results 2025-26

Beximco Pharmaceuticals PLC (AIM: BXP) reported unaudited Q3 and nine-month results ended 31 March 2026. For nine months, net sales rose 13.1% to BDT 41,428.0m (£256.9m) and profit after tax increased 34.0% to BDT 7,048.6m (£43.7m). In Q3, net sales grew 8.1% to BDT 13,627.8m (£84.5m) and PAT rose 30.6% to BDT 2,254.4m (£14.0m).

$BPMedAI 8/10

BP Chair Who Sped Up Company’s Turnaround Fired Over Conduct

BP PLC fired Chairman Albert Manifold months after he took the role, citing serious concerns about governance standards, oversight, and conduct, according to BP’s board. BP shares fell about 9.3% after the news, with the stock at 529 pence in London. The move adds to leadership churn as BP seeks a turnaround under CEO Meg O’Neill.

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.